Novo Nordisk A/s

Other

High Point Pharmaceuticals, LLC

Karo Bio Ab

Anker S Jorgensen

Knud Erik Andersen

Ursula Sonnewald

Jesper F Lau

Peter Madsen

Janos Tibor Kodra

Peter Faarup

Lars J Knutsen

Inge Thoger Christensen

Carsten Behrens

John Bondo Hansen

Paul Stanley Bury

Poul Jacobsen

John Patrick Mogensen

Christian Klarner Sams

Lise Brown Christiansen

Anders Bendtz Kanstrup

Florencio Zaragoza Dorwald

Carsten Enggaard Stidsen

Tina Moller Tagmose

Lars Jacob Knudsen

Min Teng

Henrik Sune Andersen

Lone Jeppesen

Preben H Olesen

Palle Jakobsen

Flemming E Nielsen

Dilip Ramakant Bhumralkar

Liselotte Bjerre Knudsen

Frederik Christian Gronvald

Erling Guddal

Michael David Johnson

Larry Kenneth Truesdale

Gita Camilla Tejlgaard Kampen

Christine Thomas

Ingrid Petterson

Johannes Cornelis De Jong

Dan Kiel

Anette Gundertofte

Kilburn Paul John

Frederik S Gronvald

Henrik Klitgaard

A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11&#x3b2;-hydroxy-steroid dehydrogenase type 1 (11&#x3b2;HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.

11&#x3b2;-hydroxysteroid dehydrogenase type 1 active compounds

A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.

Glucagon antagonists/inverse agonists

Novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions and methods for the treatment and/or prevention of disorders and diseases wherein an activation of the human GLP-1 receptor is beneficial, especially metabolic disorders such as IGT, Type 1 diabetes, Type 2 diabetes and obesity.

Non-peptide GLP-1 agonists

Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.

Glucagon antagonists

Substituted 3,3-diamino-2-propenenitriles, their preparation and use

The present invention relates to therapeutically active compounds of formula I ##STR1## a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in the prevention or treatment of estrogen related diseases or syndromes.

Pyrrolo[2,1,5-cd]indolizine derivatives useful in the prevention or

Pyrrolo [2,1,5-cd] indolizine derivatives useful in the prevention or

The present invention relates to 9H-indeno[1,2-b]pyrazin-3(4H)-ones and 9H-indeno[1,2-b]pyrazine-2,3(1H,4H)-diones or tautomeric forms thereof which are useful in treating neurological and psychiatric diseases based on the antagonism of the glycine binding site on the NMDA receptor complex.

9H-indeno[1,2-b]pyrazine derivatives

Novel thieno[2,3-b]pyrazine-2,3(1H,3H)-diones or tautomeric forms thereof of the formula (I) ##STR1## The compounds are useful in the treatment of neurological and psychiatric diseases.

Thieno pyrazine diones, their preparation and use

Novel O-alkylated oximes of the general formula I ##STR1## or ##STR2## wherein R.sup.1 and R.sup.2 are optionally substituted aromatic or heteroaromatic rings, R.sup.3 is hydrogen or lower alkyl, R.sup.4 is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.

Azacyclic carboxylic acid derivatives and their preparation and use

Novel O-alkylated oximes of the general formula I ##STR1## wherein R.sup.1 and R.sup.2 are optionally substituted aromatic or heteroaromatic rings, R.sup.3 is hydrogen or lower alkyl, R.sup.4 is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA re-uptake from the synaptic cleft.

Novel O-alkylated oximes of the general formula I ##STR1## wherein R.sup.1 and R.sup.2 are optionally substituted aromatic or heteroaromatic rings, R.sup.3 is hydrogen or lower alkyl, R.sup.4 is a nitrogen containing, substituted ring or an amino group carrying a substituted ring, and n and m independently are 0, 1 or 2, are potent inhibitors of GABA reuptake from the synaptic cleft.

Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which an ether group forms part of the N-substituent, the compounds thus having the general formula I ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and each represents phenyl, 2-thienyl or 3-thienyl, 2-pyrrolyl- or 3-pyrrolyl, substituted with one or more substituents selected among the following atoms or groups: hydrogen, halogen, C.sub.1-6 -alkyl, C.sub.1-6 -alkoxy or cyano; R.sup.3 and R.sup.4 each represents hydrogen or together represent a bond; m is 1 or 2 and n is 1 when m is 1 and n is 0 when m is 2; R.sup.5 and R.sup.6 each represents hydrogen or may--when m is 2--together represent a bond, and R.sup.7 is OH or C.sub.1-8 -alkoxy, p is 0 or 1 or 2, q is 0 or 1 or 2, R.sup.8 is H and C.sub.1-4 -alkyl, are potent inhibitors of GABA uptake from the synaptic cleft.

N-substituted azaheterocyclic carboxylic acids

Growing community of inventors

Copenhagen, Denmark

Anker S Jorgensen